ClinicalTrials.Veeva

Menu

Intravitreal Bevasizumab Versus Intravitreal Triamcinolone in Branch Retinal Vein Occlusion (BRVO)

S

Shahid Beheshti University of Medical Sciences

Status and phase

Unknown
Phase 2

Conditions

Branch Retinal Vein Occlusion

Treatments

Drug: Bevacizumab
Drug: Triamcinolone Acetonide

Study type

Interventional

Funder types

Other

Identifiers

Details and patient eligibility

About

This randomized clinical trial is conducted to evaluate the effect of three intravitreal injections of bevasizumab versus two intravitreal injections of triamcinolone in acute retinal vein occlusion. The outcomes are visual acuity and central macular thickness. The follow-up time is 6 months.

Enrollment

90 estimated patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Recent onset (less than 3 months) BRVO

Exclusion criteria

  • Any previous intervention

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

90 participants in 2 patient groups

Intravitreal bevacizumab
Active Comparator group
Treatment:
Drug: Bevacizumab
Intravitreal triamcinolone
Active Comparator group
Treatment:
Drug: Triamcinolone Acetonide

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems